Finch Therapeutics Group Stock Price, News & Analysis
Company Description
Finch Therapeutics Group (OTC Link: FNCH) is a publicly traded biotechnology company in the Biological Products, (no Disgnostic Substances) sector. The company has a market capitalization of $5.0M, ranking #6,729 among all listed U.S. companies by market cap.
FNCH stock has declined 47.9% over the past year. Shares last traded at $7.30.
On a trailing twelve-month basis, Finch Therapeutics Group reported revenue of $107K with net income of -$74.8M and diluted earnings per share of $-46.59. The company operates at a net profit margin of -69863.6%.
This page provides a comprehensive overview of FNCH stock, including real-time price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.
Stock Performance
Finch Therapeutics Group (FNCH) stock last traded at $7.30. Over the past 12 months, the stock has lost 47.9%. At a market capitalization of $5.0M, FNCH is classified as a micro-cap stock with approximately 1.6M shares outstanding.
Latest News
Finch Therapeutics Group has 10 recent news articles. Of the recent coverage, 4 articles coincided with positive price movement and 6 with negative movement. Key topics include stock split, earnings, management, clinical trial, conferences. View all FNCH news →
SEC Filings
Financial Highlights
Finch Therapeutics Group generated $107K in revenue over the trailing twelve months, operating income reached -$83.9M (-78374.8% operating margin), and net income was -$74.8M, reflecting a -69863.6% net profit margin. Diluted earnings per share stood at $-46.59. The company generated -$31.5M in operating cash flow. With a current ratio of 6.33, the balance sheet reflects a strong liquidity position.
Upcoming Events
Short Interest History
Short interest in Finch Therapeutics Group (FNCH) currently stands at 38 shares, down 5.0% from the previous reporting period, representing 0.0% of the float. Over the past 12 months, short interest has decreased by 96.4%. This relatively low short interest suggests limited bearish sentiment.
Days to Cover History
Days to cover for Finch Therapeutics Group (FNCH) currently stands at 1.0 days. This low days-to-cover ratio indicates high liquidity, allowing short sellers to quickly exit positions if needed.
FNCH Company Profile & Sector Positioning
Finch Therapeutics Group (FNCH) operates in the Biotechnology industry within the broader Biological Products, (no Disgnostic Substances) sector and is listed on the OTC Link.
Investors comparing FNCH often look at related companies in the same sector, including Oncotelic Therapeutics Inc (OTLC), Resverlogix (RVXCF), Institute Of Biomedical Research (MRES), ACCUSTEM SCIENCES INC (ACUT), and Cell Source Inc (CLCS). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate FNCH's relative position within its industry.